Cook, 2016 - Google Patents
Neuroprotection Following Stroke in the Gyrencephalic Non-Human Primate BrainCook, 2016
- Document ID
- 11903166533392014870
- Author
- Cook D
- Publication year
External Links
Snippet
Many pharmacological agents that have shown promise as stroke neuroprotectants in rodent studies have failed when tested in clinical trials. It was therefore suggested to evaluate such neuroprotectants in gyrencephalic non-human primate (NHP) stroke models …
- 210000004556 Brain 0 title abstract description 244
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6931678B2 (en) | Methods and compositions for treating conditions associated with aging | |
| Ramirez-Bermudez et al. | Cotard syndrome in neurological and psychiatric patients | |
| Castellano et al. | Human umbilical cord plasma proteins revitalize hippocampal function in aged mice | |
| Budde et al. | Tuberous sclerosis complex–associated angiomyolipomas: focus on mTOR Inhibition | |
| Kondziolka et al. | Transplantation of cultured human neuronal cells for patients with stroke | |
| Hammersen et al. | Genotype, clinical course, and therapeutic decision making in 76 infants with severe generalized junctional epidermolysis bullosa | |
| Shehadah et al. | Human placenta-derived adherent cell treatment of experimental stroke promotes functional recovery after stroke in young adult and older rats | |
| EP4299129A2 (en) | Dosing regimen for treatment of cognitive impairments with blood plasma products | |
| US11040068B2 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
| AU2019306477B2 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
| Gopalakrishnan et al. | Postnatal cardiovascular consequences in the offspring of pregnant rats exposed to smoking and smoking cessation pharmacotherapies | |
| Cui et al. | Platelet-derived growth factor-β expression in rabbit models of cerebral vasospasm following subarachnoid hemorrhage | |
| Cook | Neuroprotection Following Stroke in the Gyrencephalic Non-Human Primate Brain | |
| WO2015174087A1 (en) | Pharmaceutical for prevention and/or treatment of cerebral infarction | |
| Tu et al. | Somatic Braf V600E mutation in the cerebral endothelium induces brain arteriovenous malformations | |
| Yamasue | Using endophenotypes to examine molecules related to candidate genes as novel therapeutics: The “endophenotype-associated surrogate endpoint (EASE)” concept | |
| Kondziolka et al. | Neuronal transplantation for motor stroke: from the laboratory to the clinic | |
| RU2817892C1 (en) | Personalized method of bone marrow restitution for controlling progression and recurrences of various civilization diseases, preventing aging and sudden death | |
| Nelson et al. | Hiding in plain sight: Do recruited dendritic cells surround amyloid plaques in alzheimer’s disease? | |
| Huynh et al. | Myocardial infarction augments sleep to limit cardiac inflammation and damage | |
| Laiwalla | Preclinical and Clinical Stroke-A Bidirectional Approach between Insult and Intervention | |
| Rendevski et al. | Advanced 3D modeling for prediction and quantification of the perihematomal brain edema formation after ICH: implications of biochemical, radiological and clinical variables | |
| Howard | Mineralocorticoid and Glucocorticoid Signaling Differently Affect Skeletal Muscle Inflammation in Muscular Dystrophy | |
| CN114466655A (en) | Treatment of cardiovascular diseases | |
| Al-Riyami et al. | Presentations of Sultan Qaboos University Clinico-Pathologic Conferences: Sultan Qaboos University College of Medicine & Health Sciences and Sultan Qaboos University Hospital, 2014–2015 |